SCHEMBL26880189

SCHEMBL26880189

CC1(C)O[C@@H]2[C@H](O1)[C@H](N1CCOC1=O)CO[C@@H]2CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26902550 0.85 DPP4 (0.30) —
SCHEMBL26880187 0.81 — —
SCHEMBL26880186 0.81 — —
SCHEMBL23705196 0.79 — —
SCHEMBL26880184 0.78 — —
SCHEMBL23705041 0.76 CDA (0.36) —
SCHEMBL24256513 0.76 CDA (0.36) —
SCHEMBL2221786 0.65 CA1 (0.32) —
SCHEMBL12936596 0.65 CA1 (0.32) —
SCHEMBL20870542 0.65 CA1 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
Send feedback